Monoclonal Anti - Sumo-2 / 3, environ 1,0 mg / mL, clone 3H12, immunoglobulin purifié

Non disponible en dehors du Royaume-Uni et de l'Irlande

Application

Monoclonal Anti-Sumo-2/3 has been used in immunoblotting and immunocytochemistry.

Biochem/physiol Actions

Small ubiquitin-like modifier (SUMO) was identified as a post-translational protein modifier.

Small ubiquitin-like modifier 3 (SUMO3) plays a vital role in enhancing cellular responses to environmental stress. It acts as a key element of the leukemogenic network in transient myeloproliferative disorder (TMD) of the newborn/acute megakaryoblastic leukaemia (AMKL).

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

General description

Monoclonal Anti-Sumo-2/3 (rat IgG2a isotype) is derived from the hybridoma 3H12 produced by the fusion of mouse myeloma cells and splenocytes from rat immunized with a human SUMO3 fusion protein.

Small ubiquitin-like modifier 3 (SUMO3) is encoded by the gene mapped to human chromosome 21q22.3. The protein belongs to the ubiquitin-like protein family and is expressed mainly in cytoplasm.

Immunogen

human SUMO3 fusion protein

Physical form

Solution in 0.01 M phosphate buffered saline, pH 7.4, containing 15 mM sodium azide